Clinical Trials Logo

Clinical Trial Summary

Lung transplantation (LTx) remains the gold standard for treating patients with irreversible end-stage pulmonary disease. Of the major organs transplanted, survival in LTx recipients remains the lowest (mean 5 years). Despite improvements, primary graft dysfunction (PGD), as defined by respiratory insufficiency and edema up to 72 hours post LTx, remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) which is the leading cause of late mortality. PGD develops within the first 72 hours after LTx. The development of CLAD increases quickly with cumulative incidence of 40-80 % within the first 3-5 years. There is a general lack of efficient treatments for PGD and CLAD. Prevention of PGD is therefore of crucial importance and has a direct impact on survival. The present study is a randomized controlled study which aims to compare patients undergoing LTx with and without the utilization of cytokine adsorption.


Clinical Trial Description

Early intolerance to the newly transplanted lung starts at the time of transplantation and results in PGD driven by an intense inflammatory response. Cytokines play a critical role as signaling molecules that initiate, amplify, and maintain inflammatory responses both locally and systemically. The use of cytokine filtration devices to target middle- and low-molecular weight molecules has been shown to reduce levels of a diverse number of cytokines. These results have been demonstrated in the in vitro reduction of pathogen-associated molecular pattern molecules (PAMPS) and damage associated molecular patterns (DAMPS) as well as in in vivo studies involving orthotopic heart transplantation and kidney transplantation. Cytokine adsorption has been used successfully in clinical applications to both heart and kidney transplantation. The present study is a randomized controlled study which aims to collect preliminary data on the efficacy of a medical device through the comparison of patients undergoing LTx with and without cytokine adsorption. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05526950
Study type Interventional
Source Lund University Hospital
Contact Sandra Lindstedt, MD,PhD
Phone +46737220580
Email sandra.lindstedt_ingemansson@med.lu.se
Status Recruiting
Phase N/A
Start date September 7, 2023
Completion date December 31, 2029

See also
  Status Clinical Trial Phase
Recruiting NCT05916495 - An Evaluation of Remote Care (Questionnaire+Hybrid) in Patients Who Are Post-lung Transplant N/A
Enrolling by invitation NCT05950724 - RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant Early Phase 1
Active, not recruiting NCT05505422 - Routine Versus Selective Intraoperative ECMO in Lung Transplant N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Enrolling by invitation NCT04522388 - Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant N/A
Completed NCT04165161 - Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography N/A
Recruiting NCT05050955 - AlloSure Lung Assessment and Metagenomics Outcomes Study
Withdrawn NCT03258801 - Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
Completed NCT04892719 - 4DX Functional Lung Imaging in the Diagnosis of Chronic Lung Allograft Dysfunction After Lung Transplantation N/A
Completed NCT03221764 - Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients Phase 2
Active, not recruiting NCT04975607 - Live Music Therapy to Reduce Anxiety, Pain and Improve Sleep in Post-Operative Lung Transplant Patients: A Pilot Study N/A
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT03367221 - Physiological Response in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist N/A
Recruiting NCT03276403 - Primary Graft Dysfunction Score in Lung Transplantation N/A
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT05242289 - Cytokine Adsorption in Lung Transplantation N/A
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Not yet recruiting NCT04377139 - Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)
Terminated NCT03562416 - Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects Phase 2
Recruiting NCT05001074 - Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients Phase 3